Brief Title
Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy
Official Title
Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy
Brief Summary
The study proceeds with prospective, randomized, open and controlled clinical trials. The
subject of the investigator's study was the first patient diagnosed with dilated
cardiomyopathy. Subjects who agreed to participate in the study and were determined to meet
the selection / exclusion criteria were randomly assigned to each group, and the experimental
group was treated with 20 mg of olmesartan and 5 mg of rosuvastatin for 6 months, and the
control group is treated with 40 mg of valsartan and 5 mg of rosuvastatin.
Detailed Description
Myocardial viability plays an important role in improving the function of the heart. To date,
the most reproducible and objective method has been established as a method or tool for
assessing myocardial viability.
Olmesartan is known to have the strongest inhibitory ability of angiotensin receptors
compared with other angiotensin receptor binding inhibitors. Research has been reported that
statin drugs may help improve vascular endothelial function, and several researchers have
suggested that these mechanisms may affect the improvement of myocardial survival. In
addition, studies have shown that angiotensin receptor binding inhibitors and statins may
improve left ventricular function in patients with left ventricular function. However, since
the studies did not assess myocardial survival, the mechanisms could not be clearly
identified.
The purpose of this study is to investigate the effect of olmesartan on myocardial survival
in patients with dilated cardiomyopathy who have left ventricular dysfunction.
Study Phase
Phase 4
Study Type
Interventional
Primary Outcome
Rate of glucose metabolism
Condition
Dilated Cardiomyopathy
Intervention
Olmesartan 20 Mg Oral Tablet
Study Arms / Comparison Groups
Study group
Description: olmesartan 20mg with rosuvastatin 5mg once a day for 6-month
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
40
Start Date
September 1, 2019
Completion Date
December 31, 2020
Primary Completion Date
November 1, 2020
Eligibility Criteria
Inclusion Criteria:
- dilated cardiomyopathy
Exclusion Criteria:
- contraindication to angiotensin receptor blocker
- cardiogenic shock
- sensitive to rosuvastatin
- liver cirrhosis more than Child class B
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Kyungil PARK, ,
Location Countries
Korea, Republic of
Location Countries
Korea, Republic of
Administrative Informations
NCT ID
NCT04174456
Organization ID
18-215
Responsible Party
Principal Investigator
Study Sponsor
Dong-A University
Study Sponsor
Kyungil PARK, Study Director, Dong-A University Hospital
Verification Date
November 2019